Wednesday, August 21, 2024
10:06 AM EST – Theralase® Technologies Inc. : Announced that its lead drug formulation, Rutherrin® has been proven preclinically to be activated by Metformin, a common diabetes drug, without the use of light and/or radiation. Theralase® Technologies Inc. (V.TLT) shares were up $0.01 at 0.19.
Stocks in Play: Theralase® Technologies Inc., Wed, 21 Aug 2024 10:12:06 EST